6 min read
There is much for companies to consider before submitting an investigational new drug (IND) application to FDA. Planning, collecting the appropriate data, and effectively communicating with regulatory bodies can all help companies overcome challenges in the pre-clinical stage of development and efficiently prepare for IND applications.
There is no single solution to a successful regulatory strategy and IND application. Companies that want to excel in the IND application process must have an integrated and expertly coordinated approach to IND planning and execution. With proper project and risk management as well as rapid decision-making, your company can prepare a quality and timely IND application.
Three of Veristat's Regulatory experts - Mara Holinger, Kevin Hennegan, and Erin Flynn - weigh in and share their thoughts on common IND misconceptions.
Read the full article to learn more about the following:
- Important factors when planning for an IND
- Non-clinical and clinical pitfalls and misconceptions of IND applications
- Best practices for excelling in the IND application process
- And the future of IND applications
Explore related services:
Get the Latest News
Categories
- Regulatory Consulting (118)
- Regulatory Submissions (113)
- Clinical Trial Regulations (96)
- COVID-19 (46)
- Strategic Consulting (28)
- Clinical Trials (24)
- Life At Veristat (21)
- Events (16)
- Success Stories (13)
- Project Management (11)
- Decentralized Trials/Virtual Trials (9)
- Oncology (9)
- Clinical Operations/Monitoring (8)
- Medical Writing (8)
- Full-Service (7)
- CMC (6)
- Data Management (5)
- Marketing Applications (5)
- Adaptive Design (4)
- Statistics and Programming (4)
- Biologics (3)
- Cell Gene and RNA (3)
- Biometrics (2)
- Natural History (2)
- Rare Diseases (1)
2 min read
ASCO Annual Meeting
Apr 23, 2025 Veristat Events
Meet Veristat at the 2025 ASCO Annual Meeting
Advancing Oncology Therapies for Patients in Need
Veristat is proud to...